Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: COREG CR Clear all
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

NCT00648622
View directory record Official record
Conditions
Healthy
Interventions
Carvedilol Tablets 12.5 mg, Coreg® Tablets 12.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

NCT01798992
View directory record Official record
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 9, 2026, 1:46 PM EDT
Not listed Phase 2 Interventional

Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

NCT01221792
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
Columbia Northwest Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
San Diego, California • Lake Charles, Louisiana • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Effect of Carvedilol on Exercise Performance in Fontan Patients

NCT02946892
View directory record Official record
Conditions
Single Ventricle, Fontan
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

NCT00650416
View directory record Official record
Conditions
Healthy
Interventions
Carvedilol Tablets 12.5 mg, Coreg® Tablets 12.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 9, 2026, 1:46 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

"The Evaluation of Stimulant Withdrawal"

NCT00442923
View directory record Official record
Conditions
Anxiety, Relapse, Substance Addiction
Interventions
Coreg
Drug
Lead sponsor
Aaron J. Janowsky
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Sep 9, 2026, 1:46 PM EDT
Recruiting Phase 3 Interventional

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

NCT03418961
View directory record Official record
Conditions
Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Carvedilol, Laboratory Biomarker Analysis, Patient Observation
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
577
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 9, 2026, 1:46 PM EDT
Active, not recruiting Phase 2 Interventional

Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

NCT03775096
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease
Interventions
Carvedilol
Drug
Lead sponsor
Michele Tagliati, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

NCT00508365
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR capsules, Placebo, Lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Anniston, Alabama • Glendale, Arizona • Anaheim, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 9, 2026, 1:46 PM EDT
Terminated Phase 2 Interventional

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

NCT06844669
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions
Carvedilol, Empagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Blood Pressure Medications on Metabolism

NCT00642434
View directory record Official record
Conditions
Diabetes
Interventions
carvedilol, metoprolol
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
45 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure

NCT00052026
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
carvedilol, placebo
Drug
Lead sponsor
Shaddy, Robert, M.D.
Individual
Eligibility
1 Day to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2008 · Synced Sep 9, 2026, 1:46 PM EDT
Not listed Phase 4 Interventional

Rate Control in Atrial Fibrillation

NCT02251509
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Carvedilol, Metoprolol tartrate
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial

NCT00347360
View directory record Official record
Conditions
Hypertension
Interventions
lisinopril, carvedilol controlled release formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
151
States / cities
Anniston, Alabama • Birmingham, Alabama • Haleyville, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 9, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Results available

Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

NCT00430040
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Carvedilol Controlled Release (CR), lisinopril
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease

NCT00673075
View directory record Official record
Conditions
Hypertension, Coronary Artery Disease
Interventions
Nebivolol, Carvedilol
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
34
States / cities
Birmingham, Alabama • Peoria, Arizona • Buena Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2010 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects

NCT00834795
View directory record Official record
Conditions
Healthy
Interventions
Carvedilol 25 mg tablets, COREG® 25 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure

NCT00669279
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.

NCT00552708
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR, Lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 9, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional

BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)

NCT00433043
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Beta blocker (carvedilol or metoprolol succinate), CRT (cardiac resynchronization therapy)
Drug · Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.

NCT00549510
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR and lisinopril (FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

NCT00657241
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Valsartan
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 9, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Results available

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110
View directory record Official record
Conditions
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 9, 2026, 1:46 PM EDT